PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Preoperative RT with pembrolizumab is safe and results in high pCR rates and 3-year EFS, despite the lack of pembrolizumab during NAC. PD-L1 and TILs may be predictive biomarkers for preoperative anti-PD1/RT response. Reduction in TILs after adding RT to anti-PD1 highlights the importance of treatment sequencing.
Authors
- Samantha A. Kobald
- Heather L. McArthur (ORCID: https://orcid.org/0000-0002-0201-3871)
- Veerle Bossuyt (ORCID: https://orcid.org/0000-0003-0403-6791)
- Alona Muzikansky (ORCID: https://orcid.org/0000-0001-7585-8181)
- Brittany Arnold
- Dan G. Duda (ORCID: https://orcid.org/0000-0001-7065-8797)
- Mourad Tighiouart (ORCID: https://orcid.org/0000-0001-8021-5690)
- Alice Y. Ho (ORCID: https://orcid.org/0000-0002-6812-4187)
- Reva Basho (ORCID: https://orcid.org/0000-0002-4132-7523)
- Scott Karlan (ORCID: https://orcid.org/0000-0002-2689-1521)
- Stephen Lawrence Shiao (ORCID: https://orcid.org/0000-0001-7586-2885)
- Hae Lin Cho (ORCID: https://orcid.org/0000-0001-6268-3300)
- Jonathan Chen (ORCID: https://orcid.org/0000-0001-6074-9302)
- Amy Ly (ORCID: https://orcid.org/0000-0002-3889-1123)
- Philomena McAndrew
- Gaorav P. Gupta (ORCID: https://orcid.org/0000-0001-9177-552X)
- Simon Knott (ORCID: https://orcid.org/0000-0002-4018-7653)
Institutions
- University of North Carolina at Chapel Hill (US)
- Cedars-Sinai Medical Center (US)
- University of New England (US)
- Larry Ellison Foundation (US)
- Massachusetts General Hospital (US)
- Duke Medical Center (US)
- Ellison Institute of Technology (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1200/jco.24.00003
- Citations
- 21
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.93
Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Exelixis
- Moderna
- Seagen
- Genentech
- Daiichi Sankyo Europe